NCT01338805已完成2 期
A Multicenter, Open-label, Follow-up Study to Evaluate the Long-term Safety and Tolerability of BGG492 TID as Adjunctive Therapy in Patients With Partial Onset Seizures Completing Double-blind, Placebo-controlled Study CBGG492A2207 or CBGG492A2211
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 56
- 试验地点
- 1
- 主要终点
- To evaluate the long-term safety and tolerability of BGG492 capsules during the maintenance period in patients suffering from partial onset seizures
研究概览
简要总结
This long-term extension study will assess the safety, tolerability and efficacy of BGG492 as adjunctive treatment in patients with partial onset seizures.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 66 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Completed study CBGG492A2207, cooperated with the study procedures and did not experience persistent tolerability issues
- •Outpatients ≥ 45 kg (99 lb) of weight
- •Patient would like to continue BGG492 treatment and the investigator believes a reasonable benefit from the long-term administration of BGG492 may be expected
- •Treated with a stable dose of one or a maximum of three licensed Antiepileptic drugs (AEDs)and are known to take their medication(s) as directed
- •Will make themselves available for the study period and are able to record seizures and report adverse events themselves or have a caregiver who can record and report the events
- •Provided written informed consent before any extension assessment is performed
排除标准
- •Status epilepticus or seizure clusters occurring during study CBGG492A2207 or in the period between the end of study the double blind study and the start of study CBGG492A2212 for patients experiencing a treatment gap
- •Have been treated with:
- •Felbamate, unless treatment has been continuous for ≥ 2 years
- •Vigabatrin during the 26 weeks prior to the first dose of open-label medication in the extension study
- •Monoamine oxidase (MAO) inhibitors, tricyclic-antidepressants and narcotic analgesics
- •L-Dopa formulations
- •Use of concomitant medication that are potential inhibitors of Organic anion-transporting polypeptide (OATP) transporters
- •No physical examination changes suggestive of progressive neurological changes during Study CBGG492A2207
- •Used another investigational drug (other than BGG492) either at the time of enrollment in this extension study or within 5 half-lives prior to enrollment in this extension study
- •History of hypersensitivity to the study drug or to drugs of similar chemical classes (e.g. sulfonamides) or had multiple drug allergies or one or more severe drug reactions to an Antiepileptic drugs (AEDs), including dermatological reactions
- •Pregnant or nursing (lactating) women
- •Other protocol-defined inclusion/exclusion criteria may apply
研究组 & 干预措施
BGG492
Experimental
hard gelatin capsule for oral administration at 50 mg TID, 100 mg TID or 150 mg TID
干预措施: BGG492 (Drug)
结局指标
主要结局
To evaluate the long-term safety and tolerability of BGG492 capsules during the maintenance period in patients suffering from partial onset seizures
时间窗: 38 weeks
By measuring the number and percent of patients having any AE (advent event) by primary system organ class and/or preferred term. By laboratory, vital sign, and ECG data, summary statistics of values and change from baseline
次要结局
- Seizure counts: To evaluate the maintenance of efficacy and safety as assessed in percent change of seizure frequency of BGG492 capsules from the original Baseline Period to the Open-label Extension Maintenance Phase.(38 weeks)
- To evaluate long-term efficacy and safety by summarizing the number and percentage of patients who discontinue due to unsatisfactory therapeutic response effect and for all other reasons.(30 weeks)
- Responder rate: To evaluate the maintenance of efficacy by the change in responder rate and numbers of patients becoming seizure free from the original Baseline Period to the Open-label Extension Maintenance Phase.(38 weeks)
- To evaluate the efficacy over time by the change in partial seizure frequency original Baseline Period in the double-blind study CBGG492A2207 to the Open-label Extension Maintenance Phase.(38 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset SeizuresPartial Onset SeizuresNCT01147003Novartis93
已完成
2 期
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque PsoriasisChronic Plaque PsoriasisNCT03010527UCB Biopharma SRL217
已完成
2 期
An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)Thrombocythemia, EssentialPrimary MyelofibrosisNCT05223920Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)80
终止
3 期
Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisNCT05866926Ferrer Internacional S.A.201
已完成
3 期
Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)Multiple Sclerosis, Relapsing-RemittingNCT02555215Biogen20